Nacuity Says First Patient Dosed in Global Phase 3 Trial
Nacuity Pharmaceuticals announced that the first patient has been dosed in a global confirmatory Phase 3 trial of NPI-001 tablets for retinitis pigmentosa associated with Usher syndrome.
Related stories
New Era Energy and Digital raises funds through a PIPE
New Era Energy and Digital (NUAI) shares fell sharply after the company raised funds through a PIPE, according to the headline.
M impact | EQUITY | Oct 29, 2026, 12:26 PM UTC
Silicom Q3 Revenue Jumps 71%
Silicom said Q3 revenue rose 71% year over year.
M impact | EQUITY | Oct 29, 2026, 12:26 PM UTC
West Pharma executive says GLP-1 drugs helped drive growth in India and China
A West Pharma executive said GLP-1 drugs helped drive growth in India and China, according to a conference call.
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Luxshare Precision Q3 Net Profit Rises 6.98% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
OMV Petrom Publishes Q3 2026 Results Presentation Transcript
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Luxshare Precision Reports Q3 Revenue Up 14.6% Year Over Year
Luxshare Precision said third-quarter revenue rose 14.6% year over year.
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC